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Introduction
Canakinumab (CAN), a selective, human anti-IL-1b
monoclonal antibody is approved for SJIA in over 30
countries. Efficacy and safety of CAN over 12 weeks
have been demonstrated in 2 phase III trials [1]. Out of
these trials >60% of the pts received a previous biologic
and were switched to CAN due to lack of efficacy or for
safety reasons, and may be more refractory to another
biologic therapy.
Objectives
To present a post-hoc evaluation of CAN efficacy in
biologic-naïve (BN) pts and those previously exposed to
biologics (BE) during the first 12-weeks.
Methods
Pooled data from CAN naïve pts, enrolled in two phase III
trials1 and an extension phase (up to interim data lock 10
August 2012) were considered. Pts (2–19 yrs) with active
SJIA were enrolled and received CAN 4 mg/kg or placebo
sc every 4 weeks for 12 weeks. CAN naïve pts who entered
the trials and received at least one dose of CAN were
included in this analysis (N=178 CAN naïve pts).
Descriptive efficacy analyses of adapted ACR-JIA
responses at Week 12 are provided for the BN and BE pts
groups.
Results
At baseline, there were 66 (37%) BN pts whereas anakinra
(ANA), tocilizumab (TCZ), etanercept (ETN) and adali-
mumab (ADA), were the biologics received by 78 (44%),
10 (6%), 58 (33 %) and 9 (5%) pts, respectively. The main
reasons for discontinuation of biologics in BE group
(n=112) was lack of efficacy (ANA, n=32; TCZ, n=7; ETN,
n=56; ADA, n=9) or safety/tolerability (ANA, n=20; TCZ,
n=4, ETN, n=0). At Week 12, the BN and BE groups were
similar in aACR-JIA 30 and 50 response rates (Week 2:
aACR-JIA 30: 80% vs 80%; aACR-JIA 50: 76% vs 67%;
Week 12: aACR-JIA 30: 76% vs 67%; aACR-JIA 50: 74% vs
65%). Numerically higher aACR-JIA 70 and 90 response
rates were achieved in BN vs. BE pts ( Week 2: aACR-JIA
70: 67% vs 52%; aACR-JIA 90: 36% vs 37%; Week 12:
aACR-JIA 70: 70% vs 55%; aACR-JIA 90: 61% vs 42%).
aACR-JIA 70 and 90 response rates were similar in pts
previously exposed to ANA vs those not exposed to ANA
at 12 weeks (aACR-JIA70: 58% vs.63%; aACR-JIA 90:47%
vs 50% ). Compared to pts who discontinued ANA due to
lack of efficacy, there was a trend towards higher aACR-
JIA 70 and 90 response rates at Week 12 in pts who
stopped ANA for other reasons (aACR-JIA70: 34% vs.74%;
aACR-JIA90: 25% vs. 63%). A higher aACR-JIA 30, 50, 70
and 90 response rates were observed in TCZ naïve pts vs.
those pts exposed to TCZ (n=10) [aACR-JIA30:
71% vs.50%; aACR-JIA50: 70% vs. 50%; aACR-JIA70:
61% vs.50%; aACR-JIA90: 49% vs. 40%]. Higher aACR-JIA
70 and 90 responses were observed for ETN naïve pts vs.
those exposed to ETN [aACR-JIA70: 67% vs. 48%; aACR-
JIA90: 58% vs. 31%]; while ADA- naïve pts had similar
responses to CAN as ADA-exposed pt (aACR-JIA 70:
61% vs 56%) and they had higher aACR-JIA 90 response
(aACR-JIA90: 50% vs. 22%).
Conclusion
In general, pts previously exposed to biologics achieved
aACR-JIA 50,70 and 90 responses to CAN quickly in
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the first 2 weeks, and maintained their response up to
Week 12; albeit at a numerically lower level than biologic-
naïve pts. These data support the consistent efficacy of
CAN across different subgroups of pts.
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